Oklahomans have unprecedented access to innovative clinical trials because of OSCTR facilities, expertise, and data resources
With OSCTR Pilot funding, training, and mentoring, 50 new investigators have garnered over $90M in external funding.
Our mission is to improve health by catalyzing clinical and translational research that addresses Oklahoma's top health priorities.
OSCTR is Oklahoma's NIH-funded IDeA-CTR that provides resources, information, and training to help individuals or communities involved in performing clinical and translational research in the state
OPHIC is the implementation science arm of a statewide network to help improve healthcare delivery assisting primary care practices to adopt evidence-based best practices for the care of their patients.
The OCTSI CRU assists medical providers to identify and conduct clinical research opportunities in Oklahoma.
https://osctr.ouhsc.edu/short-course
This seminar/workshop will provide a brief overview of study designs for and common biases affecting diagnostic test accuracy and prognostic studies. Numerical examples will be used to illustrate the impact of common biases.
3/31/2023 Noon - 1:30 pm (CDT)
Hudson College of Public Health Auditorium (CHB 150)
Lunch Provided for first 25 in-person participants
This program is intended to support community engagement to develop funded research partnerships. Funds can be used for research development activities, including convening partners, working with individuals pursuing related work, and conducting needs assessments in community settings. The funds cannot be used to support actual human-subjects research protocols, which can be funded under other OSCTR pilot research programs and/or external funding.
Pancreatic cancer is the fourth leading cause of cancer deaths in the United States, and pancreatic cancer has some of the lowest 5-year survival rates of any cancer. Early detection can improve survival rates. When pancreatic ductal adenocarcinoma is initially diagnosed at stage IV, patients have a 2.7% 5-year survival rate. When diagnosis occurs at Stage I or IIA, this improves to 34%. However, there are currently no accurate blood tests for early detection of pancreatic cancer.
Copyright © 2025 The Board of Regents of the University of Oklahoma. All rights reserved
Disclaimer
|
Copyright
|
Equal Opportunity Employer
Built and Managed by the OCTSI. Base theme by Zymphonies